A cost-effective rapid antibody card, developed indigenously by a Bangalore based start-up SperogenX Biosciences and Rajiv Gandhi Centre for Biotechnology has obtained manufacturing licence by the Central Drugs Standard Control Organization.
The rapid antibody card will help study the presence of anti-SARS-CoV-2 IgG antibodies, with 100% sensitivity and 98% specificity. It has the advantages of being cost-effective, sensitive, and rapid. It also facilitates testing of a large number of samples at any level of clinical setting, public health centres and hospitals.
The SperogenX Biosciences in collaboration with RGCB also received licence for manufacturing two more products — viral transport media (VTM) kit and a viral RNA extraction kit. The other products of SperogenX—antigen detection system, ELISA and PCR kits— are under various stages of approval from the regulatory authorities.
These products have been developed by RGCB in partnership with SperogenX Biosciences Pvt Ltd, Bengaluru, and POCT Services, New Delhi, under SARS-CoV-2 diagnostic umbrella. Of these, VTM and RNA kits have already been test-marketed. Sperogenx is the development partner and POCT is the commercial partner.